FDA Clearance Tracker · P090013-S220
REVO MRI SURESCAN IPG AND PACING SYSTEM
Last checked: Nov 20, 2026Latest source record: Aug 24, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Aug 24, 2016
Approved
Time to decision
176 days
Received Mar 1, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P090013-S220
- Device name
- REVO MRI SURESCAN IPG AND PACING SYSTEM
- Applicant
- Medtronic, Inc.
- Applicant location
- Mounds View, MN
- Received
- Mar 1, 2016
- Decided
- Aug 24, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P090013
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the expansion of MRI conditional labeling for the Amplia MRI and Compia MRI Systems to include 3T MRI.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.